WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H597531
CAS#: 78113-36-7 (free acid)
Description: Romurtide is a synthetic muramyl dipeptide analog; stimulates chemotactic mobility, phagocytic activity & superoxide production by neutrophils in mice; used for the prophylaxis of leukocytopenia during radiation therapy.
Hodoodo Cat#: H597531
Name: Romurtide
CAS#: 78113-36-7 (free acid)
Chemical Formula: C43H78N6O13
Exact Mass: 886.56
Molecular Weight: 887.120
Elemental Analysis: C, 58.22; H, 8.86; N, 9.47; O, 23.45
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 78113-36-7 (free acid) Romurtide sodium
Synonym: Romurtide; MDP-lys(L18); Nopia; DJ-7041; DJ 7041; DJ7041; DJ 7041; Muroctasin; Muroctasine;
IUPAC/Chemical Name: N2-((4R)-4-((2S)-2-((2R)-2-(((3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)oxy)propanamido)propanamido)-5-amino-5-oxopentanoyl)-N6-stearoyl-L-lysine
InChi Key: FKHUGQZRBPETJR-FZKCHLSLSA-N
InChi Code: InChI=1S/C43H78N6O13/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23-34(52)45-26-21-20-22-32(42(58)59)48-35(53)25-24-31(39(44)55)49-40(56)28(2)46-41(57)29(3)61-38-36(47-30(4)51)43(60)62-33(27-50)37(38)54/h28-29,31-33,36-38,43,50,54,60H,5-27H2,1-4H3,(H2,44,55)(H,45,52)(H,46,57)(H,47,51)(H,48,53)(H,49,56)(H,58,59)/t28-,29+,31+,32-,33+,36+,37+,38+,43?/m0/s1
SMILES Code: OC1[C@H](NC(C)=O)[C@H]([C@@H]([C@@H](CO)O1)O)O[C@@H](C(N[C@H](C(N[C@@H](C(N)=O)CCC(N[C@H](C(O)=O)CCCCNC(CCCCCCCCCCCCCCCCC)=O)=O)=O)C)=O)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 887.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Nakajima R, Yshida Y, Akahane K, Sekiguchi M, Osada Y. Stimulatory effect of romurtide on hematopoiesis in monkeys. Arzneimittelforschung. 1991 Jan;41(1):60-5. PubMed PMID: 2049113.
2: Namba K, Yamamura E, Nitanai H, Otani T, Azuma I. Romurtide, a synthetic muramyl dipeptide derivative, promotes megakaryocytopoiesis through stimulation of cytokine production in nonhuman primates with myelosuppression. Vaccine. 1997 Mar;15(4):405-13. PubMed PMID: 9141212.
3: Ueda H, Yamazaki M. Induction of tumor necrosis factor-alpha in solid tumor region by the orally administered synthetic muramyl dipeptide analogue, romurtide. Int Immunopharmacol. 2001 Jan;1(1):97-104. PubMed PMID: 11367521.
4: Niki Y, Tatara O. Therapeutic and prophylactic effects of romurtide against experimental animal infections. Adv Exp Med Biol. 1992;319:185-91. PubMed PMID: 1414593.
5: Yokouchi J, Hirabayashi S, Kanesaka N, Baba S, Amino M, Abe K. [Study on the most appropriate time for Romurtide administration (Nopia) in radiotherapy patients]. Gan To Kagaku Ryoho. 1997 Oct;24(13):1967-73. Japanese. PubMed PMID: 9350244.
6: Nakajima R, Namba K, Ishida Y, Katsuma E, Otani T, Osada Y. Synergistic effect of romurtide with ampicillin against pneumococcal pneumonia in mice. Chemotherapy. 1992;38(4):238-50. PubMed PMID: 1473363.
7: Namba K, Otani T, Osada Y. Enhancement of platelet recovery in X-irradiated guinea pigs by romurtide, a synthetic muramyl dipeptide derivative. Blood. 1994 May 1;83(9):2480-8. PubMed PMID: 8167336.
8: Yano K, Matsuoka H, Seo Y, Kounoe S, Saito T, Tomoda H. Restorative effect of romurtide for thrombocytopenia associated with intensive anticancer drug treatment and/or irradiation in patients with gastrointestinal cancer. Anticancer Res. 1995 Nov-Dec;15(6B):2883-7. PubMed PMID: 8669883.
9: Hasegawa J, Satoh A, Yagi K, Chida K. [Augmentation of immune defense mechanisms of the lung by romurtide]. Nihon Kyobu Shikkan Gakkai Zasshi. 1995 Jun;33(6):605-11. Japanese. PubMed PMID: 7666614.
10: Tatara O, Nakahama C, Niki Y. Synergistic effects of romurtide and cefmenoxime against experimental Klebsiella pneumonia in mice. Antimicrob Agents Chemother. 1992 Jan;36(1):167-71. PubMed PMID: 1590684; PubMed Central PMCID: PMC189247.
11: Namba K, Nakajima R, Otani T, Azuma I. Oral application of romurtide, a synthetic muramyl dipeptide derivative, stimulates nonspecific resistance to microbial infections and hematopoiesis in mice. Vaccine. 1996 Aug;14(12):1149-53. PubMed PMID: 8911012.
12: Suzuki K, Torii K, Hida S, Hayashi H, Hiyama Y, Oomoto Y, Takii T, Chiba T, Onozaki K. Differences in interleukin 1 (IL-1), IL-6, tumor necrosis factor and IL-1 receptor antagonist production by human monocytes stimulated with muramyl dipeptide (MDP) and its stearoyl derivative, romurtide. Immunopharmacology. 1994 Jul-Aug;28(1):31-8. PubMed PMID: 7928300.
13: Namba K, Nitanai H, Otani T, Azuma I. Romurtide, a synthetic muramyl dipeptide derivative, accelerates peripheral platelet recovery in nonhuman primate chemotherapy model. Vaccine. 1996 Oct;14(14):1322-6. PubMed PMID: 9004440.
14: Shimoda K, Okamura S, Harada N, Omori F, Niho Y. Production of interleukin-6 from macrophages by MDP-Lys (L 18), romurtide. Res Commun Chem Pathol Pharmacol. 1990 Dec;70(3):289-96. PubMed PMID: 2093210.
15: Azuma I. Review: inducer of cytokines in vivo: overview of field and romurtide experience. Int J Immunopharmacol. 1992 Apr;14(3):487-96. Review. PubMed PMID: 1618600.
16: Azuma I. Development of the cytokine inducer romurtide: experimental studies and clinical application. Trends Pharmacol Sci. 1992 Dec;13(12):425-8. Review. PubMed PMID: 1293866.
17: Azuma I, Otani T. Potentiation of host defense mechanism against infection by a cytokine inducer, an acyl-MDP derivative, MDP-Lys(L18) (romurtide) in mice and humans. Med Res Rev. 1994 Jul;14(4):401-14. Review. PubMed PMID: 8084203.
18: Maekawa Y, Anzai T, Yoshikawa T, Sugano Y, Mahara K, Kohno T, Takahashi T, Ogawa S. Effect of granulocyte-macrophage colony-stimulating factor inducer on left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol. 2004 Oct 6;44(7):1510-20. PubMed PMID: 15464336.
19: Azuma I. [Biochemical and immunological properties of the fractions of tubercle bacilli]. Kekkaku. 1998 Feb;73(2):65-70. Review. Japanese. PubMed PMID: 9545698.
20: Kotnik V, Stalc A. Potential therapeutic indications for synthetic desmuramyl MDP analogue (LK-409). Pflugers Arch. 1996;431(6 Suppl 2):R235-6. PubMed PMID: 8739351.
